Bisoprolol is a prescription beta blocker used for high blood pressure, angina and selected heart-failure care. Confidence in these clinical roles is high; this review does not supply an independently cleared best-drug ranking. NHS purpose.
- Heart-failure initiation requires clinical stability and professional monitoring.
- Do not stop suddenly or invent a home taper.
- Severe breathing difficulty, airway swelling or collapse needs emergency assessment.
- Some low-blood-sugar warning signs can be masked.
- Breastfeeding requires an infant-specific professional decision.
Table of contents
- Evidence summary
- Bisoprolol, Cardicor and brand boundaries
- Beta blockade and heart-rate effects
- Uses and stable heart failure
- Lifestyle, rehabilitation and supplements
- CIBIS-II and CIBIS-ELD: methods and money
- Side effects and urgent warning signs
- Interactions and eye drops
- Suitability, pregnancy and breastfeeding
- Taking bisoprolol and arranging follow-up
- Laboratory evidence and safety reporting
- Funding and source roles
- Frequently asked questions
- Sources and funding notes
Evidence summary
Clinical descriptions, care guidance and independently established treatment outcomes have different evidentiary roles. The table identifies what the reviewed sources can support and which financial or clinical questions remain unresolved.
| Question / approach | Evidence reviewed | Funding / conflicts | Interpretation / limits |
|---|---|---|---|
| What is it used for? | NHS and UK/US product records. | Public contributor chains unclosed; labels Tier 4/D. | Local indication/formulation matters. |
| What did CIBIS-II study? | Original methods and acknowledgment. | Merck sponsorship, Tier 4/D. | Selected HF population; efficacy excluded. |
| What did CIBIS-ELD compare? | Original design and complete declarations. | Public and Merck support, Tier 4/D. | Tolerability study; no independent winner. |
| Can feeding be cleared? | Professional product record and SPS. | Manufacturer and commissioned-service routes differ. | Infant-specific decision; limited evidence. |
Bisoprolol, Cardicor and brand boundaries
The active ingredient is bisoprolol fumarate. The reviewed US single-ingredient tablets have a hypertension licence; this is not a universal licence for every cardiac use. US product record.
The dated Cardicor leaflet lists European names including Concor COR, Emconcor CHF, Cardensiel and Sequacor. A historical shared name does not establish present stock, ownership or licence. Dated identity.
Sun’s catalogue lists its generic against Zebeta as the reference brand. That does not establish current availability of the branded medicine. Catalogue boundary.
England recorded 31,266,076 bisoprolol-fumarate community prescription items in 2025/26, BNF code 0204000H0. Original substance row.
PCA includes hospital-issued prescriptions dispensed in the community, not hospital dispensary supplies. Items are not patients, indications, quality or worldwide popularity. Counting scope.
Check the supplied ingredient and preparation with the pharmacist. Combination packs contain an additional medicine and need their own review. For broader context, see Blood Pressure Medicines and Antiarrhythmic Medicines.
Beta blockade and heart-rate effects
Bisoprolol preferentially blocks beta-1 receptors, but selectivity is not absolute. The label describes slowing of heart rate; selectivity does not guarantee freedom from breathing problems. Mechanism and warning.
Beta blockers have different properties and uses. A class indication, such as migraine or anxiety, does not establish that bisoprolol is the appropriate individual treatment. Class boundaries.
Mechanism helps explain why clinicians review a medicine, but it cannot rank alternatives or predict an individual outcome. A change in a physiological measurement is different from a demonstrated reduction in serious events. Do not use an explanation of receptor activity to calculate your own dose or substitute another beta blocker.
Uses and stable heart failure
UK indications include hypertension, stable angina and stable reduced-function heart failure; confirm formulation. UK roles.
Cardicor’s dated professional record requires stable heart-failure initiation and monitoring of pressure, pulse and worsening symptoms. An acute deterioration is not a home starting indication. Stability and monitoring.
Heart-failure care depends on its type, stage, cause and coexisting problems. Medicines, selected procedures and rehabilitation can have different roles in the care plan. Condition context.
Ask what the prescription is treating and which service reviews it. The same ingredient can be used for different reasons; an online medicine list is not a diagnosis. Clarify what a successful review would assess, who receives readings and how to contact the team between appointments.
Lifestyle, rehabilitation and supplements
High blood pressure may have no symptoms. NHS advice supports balanced eating, appropriate activity, weight management, less salt, smoking cessation and alcohol review. Condition advice.
For heart failure, NHS advice includes a rehabilitation assessment for safe activity, prescribed treatment and attention to sudden weight gain that may reflect fluid build-up. Supported care.
Agree an activity and symptom plan with the team. Do not turn an exercise target from a general page into a requirement during acute illness. Bring the exact labels of supplements and nonprescription products to the pharmacist, including powders, mixtures and products marketed for circulation or energy.
No independently cleared supplement replacement for bisoprolol is established here. A “natural beta blocker” description is not evidence that a retail product has the same action, safety or clinical role. This review does not rank supplement brands or convert a laboratory finding into a prescription.
CIBIS-II and CIBIS-ELD: methods and money
CIBIS-II was a double-blind placebo-controlled trial in selected symptomatic reduced-function heart failure, with all-cause mortality as its primary endpoint. It stopped early after a planned interim analysis. Recent instability limits extrapolation. Original methods.
CIBIS-ELD compared bisoprolol with carvedilol in older adults with reduced or preserved pumping function. Its primary endpoint concerned tolerability of dose escalation, not mortality superiority. Original design.
Both original papers report manufacturer support: Tier 4/D; efficacy estimates are excluded.
The paper reports no funder control, but Merck’s grant still counts as industry support. Grant boundary.
Randomisation supports appraisal of study design; the financial chain needs a separate check. Excluding sponsored estimates from this verdict does not demonstrate that prescribed treatment is ineffective. It limits this review’s independent conclusion. No personal benefit probability or comparative drug ranking is supplied.
Side effects and urgent warning signs
Beta blockers can cause fatigue, dizziness, cold hands or feet, sleep disturbance and sexual difficulties. Do not drive or operate machinery while dizzy; persistent troublesome effects merit review. Impairment and adverse effects.
Jaundice, unusual heartbeat or worsening heart failure: call NHS 111 now (UK), or local urgent care. Symptoms alone do not prove causation. Serious symptoms.
Sudden throat or tongue swelling, difficulty swallowing, severe breathing difficulty or collapse can indicate anaphylaxis: call the local emergency service. Do not wait for a rash. Emergency recognition.
Severe breathing difficulty or impaired responsiveness needs emergency help. Worsening breathlessness or sudden weight gain needs prompt assessment. Bring the pack without delaying care. Urgent condition advice.
Explain when symptoms began, what changed and which products were taken. A side-effect list is neither a complete diagnosis nor a reason to delay urgent assessment.
Interactions and eye drops
Pressure/rhythm medicines, NSAID painkillers and alcohol can cause combination problems. Supply the complete product list before adding a treatment. Selected interaction groups.
Verapamil/diltiazem combinations are generally not recommended; beta-blocker eye drops add systemic effects. Clonidine withdrawal needs coordinated prescribing. Interaction boundaries.
Include inhalers, drops, recently stopped medicines, occasional painkillers and supplements. An interaction review may lead the professional to monitor, choose an alternative or change a prescription; a warning does not tell you which treatment to stop. A product being available without a prescription does not make every combination appropriate. This guide is not a complete interaction checker.
Suitability, pregnancy and breastfeeding
Severe asthma, selected conduction problems, symptomatic slow pulse/low pressure and acute decompensated failure are contraindications. Other lung or circulation problems need individual assessment. Suitability distinctions.
Low-glucose warning signs can be masked: arrange diabetes and fasting review. Glucose caution.
Tell the procedure team about bisoprolol, anaesthesia and allergy-desensitisation treatment. The dated leaflet flags these precautions. Procedure and allergy cautions.
UK pregnancy use requires clear necessity and monitoring; breastfeeding is not recommended. Discuss the plan with the specialist. Pregnancy context.
SPS permits cautious breastfeeding use, with alternatives preferred when appropriate. Its advice covers full-term healthy infants; poor feeding, lethargy, inadequate weight gain or other concerning signs require assessment. Evidence is limited. Professional scope.
Seek specialist pregnancy/infant advice; do not independently change treatment.
Taking bisoprolol and arranging follow-up
Follow the supplied instructions. Never double a forgotten dose; contact the prescriber after several missed doses. Do not stop suddenly; reductions need professional supervision. Taking and continuity.
More than the prescribed amount needs immediate medical advice, even before symptoms develop. In the UK, contact NHS 111; elsewhere use the local urgent or poison-information service. Excess-dose advice.
An appropriate cuff, supported arm and repeat measurements help reliable blood-pressure measurement. Agree how readings are recorded and communicated; a home result is not a dose instruction. Measurement context.
Confirm the follow-up appointment, the responsible service and the contact route for worsening symptoms or supply problems. If swallowing tablets is difficult, ask about the actual preparation rather than assuming it can be crushed or divided. Keep a medicine list for travel and procedures. This guide provides no starting dose, target pulse, pressure threshold, home titration, taper or missed-dose timing algorithm.
Laboratory evidence and safety reporting
Animal and cell studies do not establish human benefit, a safe personal dose or suitability of a supplied preparation. They are excluded from the clinical verdict. Their inclusion in a product document does not make them a substitute for appropriately designed human evidence and a financial review.
Yellow Card receives suspected adverse-effect reports. Reporting is separate from medical care and does not establish causation or an individual event rate. Reporting service.
The funding map separates a company’s commercial revenue, a particular trial’s backer and an author’s declared relationship. Current ownership does not establish a historical payment. Public hosting does not make manufacturer content independent, and a permitted gift does not establish that a named gift was received. Unverified allocations remain unverified.
Funding and source roles
Research funding at a glance
33 disclosure entries. The counts below summarize independence tiers explicitly assigned in this article. They count disclosures, not studies, funding amounts or evidence quality.
Consult this article’s source and funding notes for named funders, countries, relationships and exceptions where available. Institutional backing, researcher interests and trial sponsorship are separate questions. Public funding alone does not establish independence; commercial ties alone do not prove a claim false. This overview is not a new financial audit.
The source-specific map separates documented institutional funding from disease-page payments and trial sponsorship. Unknown allocations remain unknown. A public agency, charity or academic address does not by itself establish independent treatment efficacy.
| Source | Funding / backers | Country / jurisdiction | Independence | Credibility / incentives / gaps |
|---|---|---|---|---|
| NHS bisoprolol | Website funding policy. Exact page/contributor/study interests unclosed. | United Kingdom; national NHS website. | Tier 2; public context, provisional | B provisional. January 8, 2026. Education, not independent comparative efficacy. |
| NHS beta blockers | Shared national NHS website route below. Exact page/contributor/study interests unclosed. | United Kingdom; national NHS website. | Tier 2; public context, provisional | B provisional. September 4, 2026. Education, not independent comparative efficacy. |
| NHS high blood pressure | Shared national NHS website route below. Exact page/contributor/study interests unclosed. | United Kingdom; national NHS website. | Tier 2; public context, provisional | B provisional. July 19, 2024. Education, not independent comparative efficacy. |
| NHS heart failure | Shared national NHS website route below. Exact page/contributor/study interests unclosed. | United Kingdom; national NHS website. | Tier 2; public context, provisional | B provisional. June 26, 2026. Education, not independent comparative efficacy. |
| NHS anaphylaxis | Shared national NHS website route below. Exact page/contributor/study interests unclosed. | United Kingdom; national NHS website. | Tier 2; public context, provisional | C provisional. June 21, 2023. Review due June 2026, now overdue. Education, not independent comparative efficacy. |
| NHS blood pressure test | Shared national NHS website route below. Exact page/contributor/study interests unclosed. | United Kingdom; national NHS website. | Tier 2; public context, provisional | B provisional. November 25, 2025. Education, not independent comparative efficacy. |
| UK generic SmPC, September 2026 | Viatris holder, Potters Bar. Commercial finance. | United Kingdom product record. | Tier 4; manufacturer source | D. Selected clinical context; efficacy excluded. |
| UK generic leaflet, September 2026 | Viatris holder; UK/EU manufacturers listed, supplied-pack plant unverified. Shared commercial route below. | United Kingdom leaflet. | Tier 4; manufacturer source | D. Selected taking and glucose cautions; no home regimen. |
| Cardicor SmPC, November 2020 | Merck Serono Ltd, Feltham. German Merck group route documented below. | United Kingdom; 5 New Square, Bedfont Lakes Business Park, Feltham. | Tier 4; manufacturer source | D. Dated stable reduced-function HF role; current stock unverified. |
| Cardicor leaflet, July 2021 | Merck Serono Ltd, Feltham; Merck S.L., Mollet del Vallés, Spain listed plant. Actual pack unverified. | United Kingdom leaflet; dated European brand names. | Tier 4; manufacturer source | D. Dated identity and procedure/allergy cautions, corroborated by current professional record; no stock inference. |
| Sun US label, October 2024 | Harman Finochem manufacture; Sun distribution, Cranbury, New Jersey. Group finance; Host finance. | United States label; listed Shendra, Maharashtra, India plant. | Tier 4; manufacturer source | D. Hypertension licence, mechanism and safety only; efficacy excluded. |
| Sun US product catalogue | Seller listing; shared Sun commercial route below. | United States catalogue. | Tier 4; seller source | D. Zebeta reference-brand column; not proof branded stock or ownership. |
| SPS beta blockers and breastfeeding | Commissioning route. Exact host, contributor and underlying study money unclosed. | United Kingdom NHS service. | Tier 2; clinical context, provisional | B provisional. August 2023; limited evidence, full-term healthy-infant scope. |
| CIBIS-II original paper, 1999 | E. Merck, Darmstadt sponsorship; Merck KGaA representatives listed. Independent statistical centre does not remove funding. | European trial; German sponsor. | Tier 4; manufacturer-funded trial | D. Original methods/acknowledgment read; full historical personal payments unclosed. Efficacy excluded. |
| CIBIS-ELD original paper, 2011 | German ministry grant 01GI0205; Charité sponsor; Merck unrestricted grant. Düngen/Inkrot/Dietz report Merck support; Düngen/Dietz equipment from Roche/Biosite; Tahirović support from Merck/Getemed/ResMed. | German coordination; other historical backer jurisdictions unclosed. | Tier 4; manufacturer-supported trial | D. Published declarations read; credited editor's payer unclosed. Unrestricted grant does not clear independence. Efficacy excluded. |
| Merck group structure, 2025 | Family stake through E. Merck KG; remaining capital publicly traded. Commercial sectors; no historical trial allocation supplied. | Germany; Darmstadt group. | Tier 4; seller financial record | D. Own current structure; not evidence of a specific 1999 cheque or personal payment. |
| Merck healthcare business, 2025 | Medicine commercialisation and healthcare sales; no exact bisoprolol budget. | Germany; international business. | Tier 4; seller financial source | D. Own sector disclosure; financial context only. |
| Merck shareholdings, December 2025 | Lists Merck Serono Ltd, Feltham as a consolidated subsidiary. | Germany parent; United Kingdom subsidiary. | Tier 4; seller corporate record | D. Actual group link; no assumption about every generic or foreign brand. |
| Merck company information, 2025 | Company-filed consolidated accounts; business interests remain commercial. | Germany; Frankfurter Strasse 250, 64293 Darmstadt. | Tier 4; seller institutional record | D. Actual registered location; not a medicine factory census. |
| Viatris Form 10-K, 2025 | Branded/generic medicine sales and public shareholders; exact label/trial payments unclosed. | United States; 1000 Mylan Boulevard, Canonsburg, Pennsylvania. | Tier 4; seller financial source | D. Company-filed SEC report; commercial incentive, no ingredient allocation. |
| Sun consolidated accounts, 2025/26 | Branded/generic/API commercial sales; US distributor listed wholly owned. Current accounts do not allocate historical trial money. | India; SPARC, Tandalja, Vadodara registered office. | Tier 4; seller financial source | D. Selected revenue, business and subsidiary notes read; precise product allocation unclosed. |
| Harman business and contact | API, formulations and contract-manufacturing business. Complete ownership, investors and audited revenue unverified. | India; 107-A Vinay Bhavya Complex, C.S.T. Road, Mumbai. | Tier 4; manufacturer institutional source | D provisional. Own commercial routes/contact; not a cleared financial ledger. |
| England PCA substances, 2025/26 | Agency accounts. Exact statistics allocation/contributor interests unclosed. | England community dispensing. | Tier 2; public statistics, provisional | B provisional. Actual row/cells checked; items do not establish benefit. |
| PCA methodology, June 2026 | Shared NHSBSA institutional route below; exact programme allocation unclosed. | United Kingdom; England dataset. | Tier 2; public definitions, provisional | B provisional. Counting scope, not worldwide prescribing. |
| MHRA Yellow Card | Regulator finance. Exact reporting-service allocation/interests unclosed. | United Kingdom regulator. | Tier 3; reporting context, provisional | B provisional. Suspected-event reporting is separate from care and causation. |
| NHSBSA accounts, 2025/26 | DHSC Parliamentary funding plus operating service/contract income; student-support receipts separately treated. Exact PCA allocation not identified. | United Kingdom; Newcastle upon Tyne. | Tier 3; own financial report | B provisional. Statutory accounts; selected funding notes read. Institutional route only. |
| NHS content policy | DHSC website funding stated; no advertising/corporate sponsorship; contributor declarations required. Policy reviewed 2022, review due 2025. | United Kingdom; national NHS website. | Tier 3; own policy | B provisional. Public accountability; overdue policy review and public contributor-register gaps. No trial clearance. |
| SPS service commissioning | NHS England commissioning with nine host trusts/subcontractors. Published arrangements run to 31 March 2026; renewal and individual provider money unclosed. | United Kingdom; distributed providers, no single HQ verified. | Tier 3; own service statement | B provisional. Contract disclosure; dated coverage does not clear each author/page. |
| NHS England accounts, 2025/26 | DHSC grant-in-aid principally; additional service, research and consolidated charge/other income. Parent and consolidated routes differ; SPS allocation unidentified. | United Kingdom; Leeds contact address. | Tier 3; own financial report | B provisional. Selected notes read; commissioner finances do not replace host-trust ledgers. |
| MHRA accounts, 2025/26 | DHSC grant-in-aid plus statutory industry fees, customer/service income, research grants and biological-standard sales. | United Kingdom; London/Canary Wharf and South Mimms sites. | Tier 3; own financial report | B provisional. Selected current income notes read; exact safety-alert allocation unclosed. |
| NLM FY 2027 justification | FY 2026 enacted funding distinguished from FY 2027 request. Institutional grants/contracts/intramural routes; DailyMed allocation and individual gifts unclosed. | United States; Bethesda NIH library. | Tier 3; own budget report | B provisional. Selected actual budget table read; public hosting does not make labels independent. |
| NLM appropriations index | Congressional justification index; 2026 consolidation described as a proposal. Current 2027 original separately read above. | United States; 8600 Rockville Pike, Bethesda. | Tier 3; own institution record | B provisional. Location/index only; no completed restructuring inferred. |
| NIH gift-administration policy | Conditional/unconditional gift authority with conflict checks; supplementary routes include authorised foundation transfers. Authority does not establish a named NLM donation. | United States; NIH-wide policy. | Tier 3; own financial policy | B provisional. Actual policy read; donor receipts and exact medicine-page allocations unclosed. |
Frequently asked questions
Is bisoprolol safe for everyone with asthma? No. Lung suitability requires clinical assessment; selectivity is not absolute. Warning context.
Can I stop when readings improve? Do not stop suddenly or invent a taper. Continuity warning.
Can I take bisoprolol while breastfeeding? Discuss it with the specialist. SPS advice covers full-term healthy infants and requires an individual decision. Feeding scope.
Is Zebeta still available? The catalogue names a reference brand, not verified branded stock. Listing limits.
Sources and funding notes
UK generic records: September 2026. Cardicor records are dated November 2020/July 2021, used within stated identity and safety limits. The reviewed US label was revised October 2024 and remains its listed version; a seller catalogue links an older October 2023 insert. SPS feeding advice was updated August 2023; its complete bibliography is available on request and was not retrieved. Original-paper replicas supplied the selected methods and full published funding/declarations of CIBIS-II and CIBIS-ELD; direct publisher/repository access was limited. Historical payments and complete backer financial chains remain unclosed. No outcome estimates from these trials or labels are included. Current accounts establish institutional or commercial routes, not exact page allocations. Local product information and clinical review govern decisions.
- NHS bisoprolol — Purpose, selected cautions and overdose
- NHS beta blockers — Class boundaries, impairment and interactions
- NHS high blood pressure — Lifestyle and asymptomatic disease
- NHS heart failure — Care context and severe symptoms
- NHS anaphylaxis — Emergency recognition
- NHS blood pressure test — Measurement context
- UK generic SmPC, September 2026 — Professional product information
- UK generic leaflet, September 2026 — Patient product information
- Cardicor SmPC, November 2020 — Dated brand and stability boundary
- Cardicor leaflet, July 2021 — Dated aliases and selected cautions
- Sun US label, October 2024 — US jurisdiction boundary
- Sun US product catalogue — Reference-brand identity
- SPS beta blockers and breastfeeding — Infant-specific professional advice
- CIBIS-II original paper, 1999 — Trial design and sponsorship
- CIBIS-ELD original paper, 2011 — Tolerability design and financial ties
- Merck group structure, 2025 — Group ownership
- Merck healthcare business, 2025 — Backer revenue route
- Merck shareholdings, December 2025 — Holder ownership boundary
- Merck company information, 2025 — Backer jurisdiction
- Viatris Form 10-K, 2025 — Generic-holder revenue
- Sun consolidated accounts, 2025/26 — Distributor ownership and revenue
- Harman business and contact — Listed manufacturer business
- England PCA substances, 2025/26 — Prescribing context
- PCA methodology, June 2026 — Dataset limits
- MHRA Yellow Card — Safety reporting
- NHSBSA accounts, 2025/26 — Institutional finance
- NHS content policy — Dated website funding policy
- SPS service commissioning — Programme financial route
- NHS England accounts, 2025/26 — Commissioner finance
- MHRA accounts, 2025/26 — Safety regulator finance
- NLM FY 2027 justification — Label-host institution finance
- NLM appropriations index — Host location and budget provenance
- NIH gift-administration policy — Gift authority, not receipt
Educational research reviewed 4 October 2026. Diagnosis and treatment require a qualified clinician; this article does not provide an individual prescription or replace urgent assessment.
Have a question — or want us to cover something?
Ask about anything on this page, or request the next deep dive: an ingredient, a supplement, or a health concern. We use published research, evidence syntheses, and regulatory guidance, with clear source links.
One daily research roundup
Get the topics, key findings and links from our new articles in one email. At most one digest a day, only when there is something new.